The current valuation score of Larimar Therapeutics Inc is 6.11, ranking 337 out of 385 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.78, which is -36.04% below the recent high of -1.14 and -785.20% above the recent low of -15.78.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.